Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amag Pharmaceuticals and Takeda Canada have announced that Health Canada granted marketing approval for intravenous (IV) Feraheme (ferumoxytol) Injection, that is used as an iron replacement therapy to treat iron deficiency anemia (IDA) in chronic kidney disease (CKD).
Subscribe to our email newsletter
Takeda entered into an agreement with Amag to exclusively market Feraheme for all therapeutic applications in Canada.
Amag will receive a milestone payment of $3m, upon the first commercial sale of Feraheme in Canada.
Amag interim president and CEO Frank E Thomas said the approval by the agency is key milestone for the company and would bolster its efforts in expansion.
"To that end, we have marketing applications for ferumoxytol to treat IDA in adult CKD patients currently under review in other regions, including Europe," Thomas added.